CLINICAL FEATURES IN RENAL CELL CANCER PATIENTS IN TKI ERA: AN ANALYSIS OF WEB-BASED REGISTRY DATA, KOREA CANCER STUDY GROUP, GU & GY COMMITTEE, KCSG GU10-12

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Korean Cancer Study Group, GU & GY cancer committee carried out a multicenter web-based registration of renal cell cancer patients' clinical data. The aim of this RCC registry study is to investigate clinicopathologic findings of Korean renal cell cancer patients associated with diagnosis, treatment behavior and its outcomes.

Methods

A total of 979 patients from 14 hospitals were registered. The patients of the participating hospitals who were diagnosed as RCC between the years 2007 and 2011 were registered.

Results

The median age at diagnosis was 59 years and the male/female ratio was 2.35. The most common presenting symptoms and sign was pain associated palpable mass and hematuria was common. The major pathologic subtype of RCC was the clear cell type (82.1%). Other subtypes were papillary cell type (6.1%), chromophobe type (5.9%), unclassifiable type (4.1%) and others. According to Fuhrman grading system, grade 1 was 10.8%, grade 2 44.1%, grade 3 37.6% and grade 4 7.5%. Both the kidney were equally involved and bilateral involved case was nine cases. According to the TNM stage, stage I patients was 60.6%, stage II 10.6%, stage III 9.8% and stage IV 18.9%. In advanced metastatic RCC patients, the lung, bone, liver and distant lymph node were common metastatic sites. Surgical excision including metastatectmy and cytoreductive surgery was carried out in 90.2% of all patients. Anticancer immunotherapy or chemotherapy was done in ∼23.4%. In palliative settings, immunotherpay was done in 6.7%, chemotherapy with oral TKI or mTOR inhibitor in 60.7% and supportive care in 32.7%. The objective response rate of first-line palliative chemo- and/or immunotherapy among metastatic RCC patients including systemic relapsed patients was 7.5%. And the disease control rate including stable disease was 49.3%. The median overall survival in metastatic RCC patients was 19.2 months.

Conclusions

We demonstrate baseline disease characteristics as well as clinical features of renal cell cancer patients from multihospital in Korea. These data were collected from web-based registry of Korea RCC patients and analyzed using the web-based data system.

Related Topics

    loading  Loading Related Articles